valproic acid has been researched along with Metabolic Syndrome in 27 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with bipolar disorder treated with lithium often require additional antipsychotics or anticonvulsants." | 9.69 | Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. ( Bowden, CL; Calabrese, JR; Friedman, ES; Fung, V; Iosifescu, DV; Ketter, TA; Kocsis, JH; Köhler-Forsberg, O; McElroy, SL; McInnis, M; Nierenberg, AA; Ostacher, MJ; Shelton, RC; Sylvia, LG; Thase, M; Tohen, M, 2023) |
| "In the last years, a growing body of literature indicates an association between valproic acid therapy and weight gain." | 8.87 | Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. ( Chiarelli, F; Coppola, G; D'Egidio, C; Mohn, A; Verrotti, A, 2011) |
| "Evaluation of biochemical derangements related to metabolic syndrome in epileptic patients on treatment with Valproic acid." | 7.88 | Biochemical derangements related to metabolic syndrome in epileptic patients on treatment with valproic acid. ( Bobby, Z; Nisha, Y; Wadwekar, V, 2018) |
| " The aim of this study was to determine the influence of valproic acid (VPA) treatment on adiponectin, leptin levels and oxidative stress in bipolar disorder (BD)." | 7.85 | Evaluation of adiponectin and leptin levels and oxidative stress in bipolar disorder patients with metabolic syndrome treated by valproic acid. ( Akgün, S; Kahraman, A; Köken, T, 2017) |
| "The aim of this study was to compare the risk of metabolic syndrome (MS) and evaluate related factors for MS among people with epilepsy treated with valproate (VPA) or carbamazepine (CBZ)." | 7.83 | Metabolic syndrome and anticonvulsants: A comparative study of valproic acid and carbamazepine. ( Haldre, S; Kõks, S; Rakitin, A, 2016) |
| "Valproic acid (VPA) is a useful antiepileptic drug for controlling different types of epilepsy." | 7.81 | [The prevalence of obesity and metabolic syndrome in paediatric patients with epilepsy treated in monotherapy with valproic acid]. ( Carmona-Vazquez, CR; Diaz-Garcia, L; Greenawalt, SR; Pena-Landin, DM; Ruiz-Garcia, M, 2015) |
| "Patients with bipolar disorder treated with lithium often require additional antipsychotics or anticonvulsants." | 5.69 | Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. ( Bowden, CL; Calabrese, JR; Friedman, ES; Fung, V; Iosifescu, DV; Ketter, TA; Kocsis, JH; Köhler-Forsberg, O; McElroy, SL; McInnis, M; Nierenberg, AA; Ostacher, MJ; Shelton, RC; Sylvia, LG; Thase, M; Tohen, M, 2023) |
| "Aripiprazole plus a mood stabilizer has minimal impact on metabolic changes in predominantly overweight/obese BPD patients over a 52-week period." | 5.17 | Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine. ( Baker, RA; Carlson, BX; De Hert, M; Eudicone, JM; Fyans, P; Kemp, DE; Marler, SV; Rahman, Z, 2013) |
| " VPA-induced weight gain seems to be associated with many metabolic disturbances; the most frequent are hyperinsulinemia and insulin resistance, hyperleptinemia and leptin resistance." | 4.89 | Metabolic and endocrine effects of valproic acid chronic treatment. ( Belcastro, V; D'Egidio, C; Striano, P; Verrotti, A, 2013) |
| "In the last years, a growing body of literature indicates an association between valproic acid therapy and weight gain." | 4.87 | Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. ( Chiarelli, F; Coppola, G; D'Egidio, C; Mohn, A; Verrotti, A, 2011) |
| "Valproic acid (2-n-propylpentanoic acid, VPA) is well-established as a mood-stabilizer for bipolar disorder, in addition to its application as a treatment in neurological disorders such as epilepsy, migraine headaches, and chronic neuropathic pain." | 4.84 | Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review. ( Rasgon, NL; Reynolds, MF; Sisk, EC, 2007) |
| "Evaluation of biochemical derangements related to metabolic syndrome in epileptic patients on treatment with Valproic acid." | 3.88 | Biochemical derangements related to metabolic syndrome in epileptic patients on treatment with valproic acid. ( Bobby, Z; Nisha, Y; Wadwekar, V, 2018) |
| " The aim of this study was to determine the influence of valproic acid (VPA) treatment on adiponectin, leptin levels and oxidative stress in bipolar disorder (BD)." | 3.85 | Evaluation of adiponectin and leptin levels and oxidative stress in bipolar disorder patients with metabolic syndrome treated by valproic acid. ( Akgün, S; Kahraman, A; Köken, T, 2017) |
| "The aim of this study was to compare the risk of metabolic syndrome (MS) and evaluate related factors for MS among people with epilepsy treated with valproate (VPA) or carbamazepine (CBZ)." | 3.83 | Metabolic syndrome and anticonvulsants: A comparative study of valproic acid and carbamazepine. ( Haldre, S; Kõks, S; Rakitin, A, 2016) |
| "Valproic acid (VPA) is a useful antiepileptic drug for controlling different types of epilepsy." | 3.81 | [The prevalence of obesity and metabolic syndrome in paediatric patients with epilepsy treated in monotherapy with valproic acid]. ( Carmona-Vazquez, CR; Diaz-Garcia, L; Greenawalt, SR; Pena-Landin, DM; Ruiz-Garcia, M, 2015) |
| "Our study was carried out to ascertain the role of valproic acid for inducing metabolic disorders like hyperinsulinemia, insulin resistance and metabolic syndrome." | 3.77 | Fasting insulin and HOMA-index changes in patients treated with valproic acid. ( Javashvili, L; Kasradze, S; Mania, M; Okujava, N, 2011) |
| "Metabolic syndrome was more frequent in patients with epilepsy compared with healthy participants (32." | 1.56 | Metabolic syndrome and obstructive sleep apnea syndrome among patients with epilepsy on monotherapy. ( Ataklı, D; Balçık, ZE; Baslo, SA; Öztürk, O; Söylemez, E, 2020) |
| "73) in VPA-treated patients, but there were no associations with the VPA dosage or the homeostasis model assessment-estimated insulin resistance (HOMA-IR) index." | 1.40 | Comparison of the metabolic syndrome risk in valproate-treated patients with epilepsy and the general population in Estonia. ( Eglit, T; Haldre, S; Kõks, S; Lember, M; Rakitin, A, 2014) |
| "Metabolic syndrome was more frequently associated with VPA-treated patients (41." | 1.34 | Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. ( Kim, JY; Lee, HW, 2007) |
| "Weight gain is a known side effect of valproate (VPA) therapy, which is associated with hyperinsulinemia and polycystic ovary-like syndrome and unfavorable lipid changes in women." | 1.33 | Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. ( Isojärvi, J; Knip, M; Pakarinen, A; Pylvänen, V, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (22.22) | 29.6817 |
| 2010's | 17 (62.96) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Marjani, M | 1 |
| Dolab, N | 1 |
| Kamkar, MZ | 1 |
| Amiriani, T | 1 |
| Yuzugulen, J | 1 |
| Marjani, A | 1 |
| Chang, CC | 1 |
| Chen, PS | 5 |
| Lin, JR | 1 |
| Chen, YA | 1 |
| Liu, CS | 1 |
| Lin, TT | 1 |
| Chang, HH | 3 |
| Köhler-Forsberg, O | 1 |
| Sylvia, LG | 1 |
| Thase, M | 1 |
| Calabrese, JR | 1 |
| Tohen, M | 1 |
| Bowden, CL | 1 |
| McInnis, M | 1 |
| Iosifescu, DV | 1 |
| Kocsis, JH | 1 |
| Friedman, ES | 1 |
| Ketter, TA | 1 |
| McElroy, SL | 1 |
| Shelton, RC | 1 |
| Fung, V | 1 |
| Ostacher, MJ | 1 |
| Nierenberg, AA | 1 |
| Söylemez, E | 1 |
| Öztürk, O | 1 |
| Baslo, SA | 1 |
| Balçık, ZE | 1 |
| Ataklı, D | 1 |
| Holder, SD | 1 |
| Akgün, S | 1 |
| Köken, T | 1 |
| Kahraman, A | 1 |
| Nisha, Y | 1 |
| Bobby, Z | 1 |
| Wadwekar, V | 1 |
| Belcastro, V | 1 |
| D'Egidio, C | 2 |
| Striano, P | 1 |
| Verrotti, A | 3 |
| Rakitin, A | 2 |
| Eglit, T | 1 |
| Kõks, S | 2 |
| Lember, M | 1 |
| Haldre, S | 2 |
| Lee, SY | 2 |
| Chen, SL | 2 |
| Chang, YH | 2 |
| Huang, SY | 3 |
| Tzeng, NS | 3 |
| Wang, CL | 1 |
| Wang, LJ | 2 |
| Lee, IH | 2 |
| Wang, TY | 2 |
| Chen, KC | 2 |
| Yang, YK | 4 |
| Hong, JS | 2 |
| Lu, RB | 5 |
| Carmona-Vazquez, CR | 1 |
| Ruiz-Garcia, M | 1 |
| Pena-Landin, DM | 1 |
| Diaz-Garcia, L | 1 |
| Greenawalt, SR | 1 |
| Chang, TT | 1 |
| Chu, CH | 1 |
| Chen, SH | 1 |
| Li, CL | 1 |
| Chung, YL | 1 |
| Hsieh, TH | 1 |
| Elmslie, JL | 1 |
| Porter, RJ | 1 |
| Joyce, PR | 1 |
| Hunt, PJ | 1 |
| Shand, BI | 1 |
| Scott, RS | 1 |
| Chou, CH | 1 |
| Gean, PW | 2 |
| Huang, HC | 2 |
| Lin, CY | 1 |
| Manco, R | 1 |
| Agostinelli, S | 1 |
| Coppola, G | 2 |
| Chiarelli, F | 2 |
| Mohn, A | 1 |
| Mania, M | 1 |
| Javashvili, L | 1 |
| Kasradze, S | 1 |
| Okujava, N | 1 |
| Fang, J | 1 |
| Chen, S | 1 |
| Tong, N | 1 |
| Chen, L | 1 |
| An, D | 1 |
| Mu, J | 1 |
| Zhou, D | 1 |
| Hung Chi, M | 1 |
| Hua Chang, H | 1 |
| Chou, KR | 1 |
| Chun Tsai, H | 1 |
| Kuang Yang, Y | 1 |
| See Chen, P | 1 |
| Kemp, DE | 1 |
| De Hert, M | 1 |
| Rahman, Z | 1 |
| Fyans, P | 1 |
| Eudicone, JM | 1 |
| Marler, SV | 1 |
| Baker, RA | 1 |
| Carlson, BX | 1 |
| Swartz, HA | 1 |
| Fagiolini, A | 1 |
| Pylvänen, V | 1 |
| Pakarinen, A | 1 |
| Knip, M | 1 |
| Isojärvi, J | 1 |
| Yumru, M | 1 |
| Savas, HA | 1 |
| Kurt, E | 1 |
| Kaya, MC | 1 |
| Selek, S | 1 |
| Savas, E | 1 |
| Oral, ET | 1 |
| Atagun, I | 1 |
| Kim, JY | 1 |
| Lee, HW | 1 |
| Reynolds, MF | 1 |
| Sisk, EC | 1 |
| Rasgon, NL | 1 |
5 reviews available for valproic acid and Metabolic Syndrome
| Article | Year |
|---|---|
Psychotic and Bipolar Disorders: Bipolar Disorder.
Topics: Antimanic Agents; Bipolar Disorder; Cardiovascular Diseases; Chronic Pain; Comorbidity; Family Pract | 2017 |
Metabolic and endocrine effects of valproic acid chronic treatment.
Topics: Anticonvulsants; Epilepsy; Humans; Hyperinsulinism; Insulin Resistance; Leptin; Metabolic Syndrome; | 2013 |
Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications.
Topics: Androgens; Anticonvulsants; Epilepsy; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; | 2011 |
Cardiovascular disease and bipolar disorder: risk and clinical implications.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Cardiovascular Diseases; | 2012 |
Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Contraceptives, Oral; Epilepsy; Female; Hormone | 2007 |
4 trials available for valproic acid and Metabolic Syndrome
| Article | Year |
|---|---|
Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Comb | 2023 |
Correlation of plasma brain-derived neurotrophic factor and metabolic profiles in drug-naïve patients with bipolar II disorder after a twelve-week pharmacological intervention.
Topics: Adult; Affect; Bipolar Disorder; Body Mass Index; Brain-Derived Neurotrophic Factor; Cholesterol; Fe | 2015 |
The DRD3 Ser9Gly Polymorphism Predicted Metabolic Change in Drug-Naive Patients With Bipolar II Disorder.
Topics: Bipolar Disorder; DNA; Dose-Response Relationship, Drug; Double-Blind Method; Female; GABA Agents; G | 2016 |
Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Drug | 2013 |
18 other studies available for valproic acid and Metabolic Syndrome
| Article | Year |
|---|---|
Gender and Body Mass Index-Related Serum Level of Adipokines and Metabolic Syndrome Components in Bipolar Patients Who Received Lithium and Valproic Acid.
Topics: Adipokines; Adiponectin; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Female; Humans; Leptin | 2022 |
Mitochondrial DNA Copy Number Is Associated With Treatment Response and Cognitive Function in Euthymic Bipolar Patients Receiving Valproate.
Topics: Bipolar Disorder; Cognition; DNA Copy Number Variations; DNA, Mitochondrial; Humans; Metabolic Syndr | 2022 |
Metabolic syndrome and obstructive sleep apnea syndrome among patients with epilepsy on monotherapy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Epilepsy; Female; | 2020 |
Evaluation of adiponectin and leptin levels and oxidative stress in bipolar disorder patients with metabolic syndrome treated by valproic acid.
Topics: Adiponectin; Adult; Bipolar Disorder; Humans; Leptin; Male; Metabolic Syndrome; Middle Aged; Oxidati | 2017 |
Biochemical derangements related to metabolic syndrome in epileptic patients on treatment with valproic acid.
Topics: Adolescent; Adult; Anticonvulsants; Biomarkers; Body Mass Index; Cholesterol; Cross-Sectional Studie | 2018 |
Comparison of the metabolic syndrome risk in valproate-treated patients with epilepsy and the general population in Estonia.
Topics: Adult; Anticonvulsants; Case-Control Studies; Epilepsy; Estonia; Female; Humans; Male; Metabolic Syn | 2014 |
[The prevalence of obesity and metabolic syndrome in paediatric patients with epilepsy treated in monotherapy with valproic acid].
Topics: Adolescent; Anticonvulsants; Child; Cross-Sectional Studies; Epilepsy; Female; Humans; Male; Metabol | 2015 |
Metabolic syndrome and anticonvulsants: A comparative study of valproic acid and carbamazepine.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Male; Metabolic Syndrome; Mid | 2016 |
Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.
Topics: Adiponectin; Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Comorb | 2009 |
High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan.
Topics: Adult; Analysis of Variance; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Blood Glucose | 2009 |
The metabolic syndrome in overweight epileptic patients treated with valproic acid.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Cardiovascular Diseases; Child; Comorbidity; Dyslipide | 2010 |
The role of valproate in metabolic disturbances in bipolar disorder patients.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Blood Glucose; Body Mass Index; Cholesterol, HDL; Choleste | 2010 |
Fasting insulin and HOMA-index changes in patients treated with valproic acid.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Carbamazepine; Cholesterol, HDL; Epilepsy; Female; | 2011 |
Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate.
Topics: Adolescent; Adult; Anticonvulsants; Asian People; Epilepsy; Female; Humans; Male; Metabolic Syndrome | 2012 |
The prevalence of metabolic syndrome in drug-naïve bipolar II disorder patients before and after twelve week pharmacological intervention.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Body Mass Index; Diagnostic and Statistical Manual of Men | 2013 |
Insulin-related metabolic changes during treatment with valproate in patients with epilepsy.
Topics: Adult; Anticonvulsants; Body Mass Index; Epilepsy; Female; Humans; Hyperinsulinism; Insulin; Lipopro | 2006 |
Atypical antipsychotics related metabolic syndrome in bipolar patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Carbama | 2007 |
Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy.
Topics: Adolescent; Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Carbamazepine; Comorbidity; Epil | 2007 |